Cardiovascular disease in the antiphospholipid syndrome

被引:10
作者
Amaya-Amaya, Jenny
Rojas-Villarraga, Adriana
Anaya, Juan-Manuel [1 ]
机构
[1] Univ Rosario, Ctr Autoimmune Dis Res CREA, Sch Med & Hlth Sci, Bogota 11001000, Colombia
关键词
Cardiovascular disease; antiphospholipid syndrome; traditional risk factors; novel risk factors; VASCULAR-DISEASE; ANTIBODIES; ATHEROSCLEROSIS; PATHOGENESIS; CORONARY;
D O I
10.1177/0961203314540015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.
引用
收藏
页码:1288 / 1291
页数:4
相关论文
共 50 条
  • [41] Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients
    Yelnik, Cecile M.
    Martin, Claire
    Ledoult, Emmanuel
    Sanges, Sebastien
    Sobanski, Vincent
    Farhat, Meryem
    Morell-Dubois, Sandrine
    Maillard, Helene
    Drumez, Elodie
    Launay, David
    Hachulla, Eric
    Lambert, Marc
    LUPUS, 2022, 31 (11) : 1379 - 1384
  • [42] Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
    Arachchillage, Deepa J.
    Laffan, Mike
    Pericleous, Charis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [43] Genetics of Antiphospholipid Syndrome
    Ortiz-Fernandez, Lourdes
    Sawalha, Amr H.
    CURRENT RHEUMATOLOGY REPORTS, 2019, 21 (12)
  • [44] Catastrophic antiphospholipid syndrome
    Cervera, Ricard
    Asherson, Ronald A.
    PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2006, 35 (1-2) : 181 - 186
  • [45] 'Equivocal' antiphospholipid syndrome
    Harris, EN
    Pierangeli, SS
    JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) : 81 - 85
  • [46] Immunotherapy in antiphospholipid syndrome
    Lopez-Pedrera, Ch.
    Aguirre, M. A.
    Ruiz-Limon, P.
    Perez-Sanchez, C.
    Jimenez-Gomez, Y.
    Barbarroja, N.
    Cuadrado, M. J.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 27 (02) : 200 - 208
  • [47] An Update on Antiphospholipid Syndrome
    Eleni Xourgia
    Maria G. Tektonidou
    Current Rheumatology Reports, 2021, 23
  • [48] Management of antiphospholipid syndrome
    Rahman, Anisur
    CLINICAL RHEUMATOLOGY, 2020, 39 (07) : 2111 - 2114
  • [49] The antiphospholipid syndrome: An update
    Franchini, M
    CLINICAL LABORATORY, 2006, 52 (1-2) : 11 - 17
  • [50] Complement and the antiphospholipid syndrome
    Lim, Wendy
    CURRENT OPINION IN HEMATOLOGY, 2011, 18 (05) : 361 - 365